Stereotactic body radiotherapy is an alternative to radiofrequency ablation for single HCC ≤5.0 cm
JHEP Reports · 2024-10 · 6 (10) · 101151
DOI: 10.1016/j.jhepr.2024.101151 ↗Kurz gefasst
Fachartikel in der Zeitschrift JHEP Reports, 2024-10. Verfasst von Zhoutian Yang und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guan…. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background & Aims: Radiation therapy has been refined with increasing evidence of the benefits of stereotactic body radiation therapy (SBRT) in treating hepatocellular carcinoma (HCC). In this study, we aimed to evaluate whether SBRT could serve as an alternative to radiofrequency ablation (RFA) for small HCC with a single lesion ≤5.0 cm.
Methods
Patients with a single HCC lesion ≤5.0 cm who received RFA or SBRT were included. Cumulative local/distant recurrence rate, progression-free survival, overall survival, adverse events and subsequent treatments after recurrence were analyzed.
Results
A total of 288 patients receiving RFA (n = 166) or SBRT (n = 122) were enrolled. The baseline characteristics between the two groups were comparable. The cumulative local recurrence rate in the SBRT group was significantly lower than that in the RFA group (hazard ratio [HR] 0.30, 95% CI 0.16-0.57, p 2.0 cm (HR 0.20, 95% CI 0.08-0.50, p 0.050). Adverse events were mild and easily reversible. However, more patients in the SBRT group suffered from Child-Pugh score and total bilirubin increases. More treatment options after recurrence or progression might be available for patients in the RFA group compared to those in the SBRT group (p 2.0 cm or adjacent to major vessels. Impact and implications: Stereotactic body radiation therapy (SBRT) may be used as an alternative treatment to thermal ablation for patients with BCLC stage A hepatocellular carcinoma (HCC) who are not candidates for surgical resection, including those with tumours >3 cm and those with 1 to 3 tumours. This study focused on HCC patients with a specific tumour burden, namely a single lesion ≤5.0 cm, demonstrating that SBRT could be an effective and safe alternative to radiofrequency ablation (RFA), especially for those with tumours >2.0 cm or adjacent to major vessels. The findings of this study provided robust empirical evidence supporting the utilization of SBRT in treating small HCC, while also establishing a solid foundation for future prospective clinical investigations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China.
- Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, P. R. China.
- Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, P. R. China.
Zitieren
APA
Yang, Z., Liu, S., Hu, L., Chen, J., Wang, J., Pan, Y., Xu, L., Liu, M., Chen, M., Xi, M., & Zhang, Y. (2024). Stereotactic body radiotherapy is an alternative to radiofrequency ablation for single HCC ≤5.0 cm. JHEP Reports, 6(10), 101151. https://doi.org/10.1016/j.jhepr.2024.101151
Vancouver
Yang Z, Liu S, Hu L, Chen J, Wang J, Pan Y, et al. Stereotactic body radiotherapy is an alternative to radiofrequency ablation for single HCC ≤5.0 cm. JHEP Reports. 2024;6(10):101151. doi:10.1016/j.jhepr.2024.101151
BibTeX
@article{Yang2024,
author = {Yang, Zhoutian and Liu, Shiliang and Hu, Li and Chen, Jinbin and Wang, Juncheng and Pan, Yangxun and Xu, Li and Liu, Mengzhong and Chen, Minshan and Xi, Mian and Zhang, Yaojun},
title = {Stereotactic body radiotherapy is an alternative to radiofrequency ablation for single HCC ≤5.0 cm},
journal = {JHEP Reports},
year = {2024},
volume = {6},
number = {10},
pages = {101151},
doi = {10.1016/j.jhepr.2024.101151}
}
EUVIMED